Lilly’s Search For Sepsis Biomarkers Could Provide Early Signal For Xigris Use
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Lilly is looking for sepsis biomarkers that could aid Xigris administration, exec tells FDA seminar. Data suggests Xigris, a form of activated protein C, has higher survival rates when administered early; biomarkers could be signal for use. Studies of diagnostic/prognostic role of protein C are underway